Viridian Therapeutics, Inc.

NASDAQ:VRDN

Biotechnology

Healthcare
$30.12 -0.88%

-$0.15 today

Market cap
$3.42B
Beta
0.90
P/E (TTM)
-4.7
EPS (TTM)
-$3.53
52W Low $13.18High $34.29

Volume 1.49M

Average 2.86M

VRDN Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Viridian Therapeutics, Inc.NASDAQ: VRDN

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue grows, but more slowly than its trailing trend

Q2 FY2026 revenue of $284K rose 278.7% year over year, behind the +23220.3% change in trailing-twelve-month revenue. Sequentially, it rose 101.4% from the prior quarter. Over 3 fiscal years it compounded at +241.9% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 10 analysts of $75.13M (+6.0%) for the fiscal year ending Dec 2026, a slowdown from the +23359.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$284K+101.4% QoQ
Last fiscal yearDec 2025
$70.85M+23359.9% YoY
LTMJun 2026
$71.13M+23220.3% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+278.7%-93.3%-372.0 pp
1 year+23359.9%+6.0%-23353.9 pp
3-year CAGR+241.9%+112.3%-129.6 pp
5-year CAGR+78.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
70.85M USD
Year-over-year change
+23359.9%
4-year CAGR
+121.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How VRDN compares with its peers on the latest reported figures

  • VRDN's LTM Jun 2026 revenue of $71.13M is the highest of the 4 companies compared; the peer median is $7.62M.
  • Its year-over-year change of +23220.3% is the highest of 4, against a peer median of -12.8%.
  • Over three fiscal years its annual growth of +241.9% compares with a peer median of -4.3%.
VRDN Competitors Peer median
Revenue for VRDN and competitors
Company Period LTM YoY 3-year CAGR
VRDNViridian Therapeutics, Inc.LTM Jun 2026$71.13M +23220.3%+241.9%
OCULOcular Therapeutix, Inc.LTM Mar 2026$52.04M -12.8%+0.2%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$7.62M -86.4%-8.8%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$333.14K +95.8%—
Peer median (excluding VRDN) $7.62M-12.8%-4.3%

Competitors are the stored peer set for VRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.96M1.77M314K302K70.85M
Cost of Revenue00000
Gross Profit2.96M1.77M314K302K70.85M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development56.89M100.89M159.77M238.25M338.93M
Selling, General & Admin25.81M35.18M95M61.08M95.32M
Operating Expenses82.69M136.08M254.76M299.34M434.24M
Depreciation & Amortization120K255K522K540K460K
EBITDA(79.29M)(129.13M)(235.37M)(266.36M)(337.19M)
EBITDA Margin-2676.0%-7287.4%-74957.0%-88199.7%-475.9%
Operating Income(79.73M)(134.3M)(254.45M)(299.04M)(363.4M)
Operating Margin-2690.8%-7579.2%-81035.0%-99018.2%-512.9%
Interest Income318K4.92M18.56M32.13M27.4M
Interest Expense3K486K1.85M3.05M4.95M
Other Income / Expenses315K4.43M16.72M29.09M20.79M
Income Before Tax(79.41M)(129.87M)(237.73M)(269.95M)(342.6M)
Pre-Tax Margin-2680.2%-7329.2%-75711.5%-89387.1%-483.6%
Income Tax Expense00000
Net Income(79.41M)(129.87M)(237.73M)(269.95M)(342.6M)
Net Margin-2680.2%-7329.2%-75711.5%-89387.1%-483.6%
EPS (Basic)(6.66)(3.91)(5.31)(3.98)(3.32)
EPS (Diluted)(6.66)(3.91)(5.31)(3.98)(3.32)
Weighted Avg Shares11.92M32.09M44.76M67.89M84.8M
Weighted Avg Shares (Diluted)11.92M32.09M44.76M67.89M84.8M

Viridian Therapeutics, Inc.

NASDAQ:VRDN

Intrinsic Alpha fair value

Locked

Current Price

$30.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.